News & Updates
Filter by Specialty:
Multiple myeloma quadruplet prolongs survival, induces deeper responses
02 Jan 2024
byJairia Dela Cruz
Adding subcutaneous daratumumab to the three-drug regimen containing bortezomib, lenalidomide, and dexamethasone (VRd) appears to improve outcomes for transplant-eligible patients with newly diagnosed multiple myeloma (MM), with extended disease-free periods and increased depth of response, according to the phase III PERSEUS trial.